Customising an International Disease Management Model to the Needs of Individual Countries
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 14 (2) , 39-56
- https://doi.org/10.2165/00019053-199814002-00005
Abstract
The baseline economic model for upper gastrointestinal (UGI) disease was developed in the context of patterns of care and resource use within the UK. It provided the opportunity to evaluate the extent to which an economic model developed in one country could be applied to meet the pharmacoeconomic information needs of decision makers in another. The choice of countries for analysis was restricted to countries within the International Gastro Primary Care Group (IGPCG) who had previously agreed on the appropriateness of the basic clinical algorithm to their domestic healthcare environment. This provided a potential sample of 9 countries (Australia, Austria, Germany, Italy, The Netherlands, Sweden, Switzerland, the UK and the USA) of which the UK, Germany, Sweden and Switzerland were chosen as providing a broad spectrum of strategic and operating environments in which to test the international transferability of the economic model. The process and results obtained provide valuable evidence of the extent to which economic analyses can be transferred across national borders.Keywords
This publication has 18 references indexed in Scilit:
- A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic FibrosisInternational Journal of Technology Assessment in Health Care, 1996
- A Comparative Analysis of the Pharmaceutical Market in Four European CountriesPharmacoEconomics, 1994
- The German health care system at the crossroadsHealth Economics, 1994
- Something rotten in the state of clinical and economic evaluations?Health Economics, 1994
- Pricing and Reimbursement of Pharmaceuticals in SwedenPharmacoEconomics, 1994
- The Impact of Recent Legislative Change in GermanyPharmacoEconomics, 1994
- General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method.BMJ, 1993
- Guidelines for Economic Analysis of Pharmaceutical ProductsPharmacoEconomics, 1993
- Factors associated with high-quantity prescriptions of benzodiazepines in SwedenSocial Science & Medicine, 1993
- Cost‐effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status?Health Economics, 1992